Preoperative Stent Study
Randomized Study Comparing the Effect of Plastic Stents to That of Expandable Metal Stents Prior to Pancreaticoduodenectomy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Patients suffering from a locally invasive tumour process in the Periampullary area usually seek medical attention because of jaundice. Not only do patients suffering from jaundice show significant symptoms of exhaustion and purities, but they are also at higher risk for developing post-operative complications. Experimentally, the liver exhibits a reduced capacity for tolerating ischemia in the presence of jaundice. Several different etiologic factors suggest cause complication such as presence of toxic substances as bilirubin and bile salts, impaired nutritional status, effects of endotoxins, bacterial translocation, modulation of the inflammatory cascade with cytokine release, reduction of cellular immunity and nutritional. These complications primarily consist of septic complications (cholangitis, abscesses, and leakage), haemorrhage, impaired wound healing and renal disorders. Summarily, these issues have motivated pre-operative bile flow drainage by way of stent. Traditionally, pre-operative bile flow drainage has been achieved by insertion of a EP because these are considered easy to remove and cause less tissue reaction in the bile ducts. However, multiple studies have found the disadvantage with the EP is that it provides poorer bile drainage than the SEMS.
In palliative situations, metal stents have been associated with fewer side-effects in the form of fever relapse of jaundice, etc. These effects are likely due to better bile flow through the stent. It remains unclear if metal stents can provide similar advantages in the curative situation.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden, 14186
- Karolinksa University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The primary inclusion criteria are all patients with operable Periampullary cancer and jaundice who have not previously undergone bile flow drainage.
Exclusion Criteria:
- Define as failed ERCP, patients who have previously undergone bile flow drainage or radical surgery is not possible.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: plastic stent
Stent insertion
|
Patient randomizes to metal or plastic insertion prior to Whipple procedure
Other Names:
|
|
Active Comparator: metalic stent
Stent inserttion
|
Patient randomizes to metal or plastic insertion prior to Whipple procedure
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Intra-operative measurement of the Culture from the bile.
Time Frame: Intraoperativt
|
Intraoperativt
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Intraoperative measurements of inflammatory reaction in the liver, hepatoduodenal ligament and around the bile ducts with biopsies. Stent dysfunction and cholangitis after ERCP and pre-operative bile flow relief. Postoperative analysis.
Time Frame: Perioperative
|
Perioperative
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Lars Enochsson, MD, PhD, Karolinksa Institutet
- Study Director: Urban Arnelo, M.D., Karolinska Institutet
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ¨2006/220-31/4
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreas Cancer
-
NCT02681796CompletedPancreatic Cancer | Pancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the Pancreas
-
NCT01446458CompletedPancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, Pancreatic
-
NCT07358208Enrolling by invitationFamily History of Pancreas Cancer
-
NCT04123574WithdrawnPancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, Pancreatic
-
NCT02608229TerminatedPancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the Pancreas
-
NCT02311361CompletedPancreatic Neoplasms | Pancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the Pancreas
-
NCT01771146UnknownPancreas Cancer | Localized Pancreas Cancer | Non-metastatic Pancreas Cancer
-
NCT02905578CompletedAdenocarcinoma | Pancreatic Neoplasms | Pancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, Pancreatic
-
NCT07592819Not yet recruitingPancreatic Cancer Resectable | Pancreas Adenocarcinoma (MSI-H)
-
NCT05351983CompletedPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreas Adenocarcinoma | Pancreas Cancer | Pancreas Neoplasm
Clinical Trials on Plastic and metalic stent inserion
-
NCT01148199CompletedBiliary Stricture | Biliary Anastomotic Stenosis
-
NCT01191814CompletedPancreatic Cancer | Obstructive Jaundice
-
NCT06960733CompletedBiliary Tract Cancer | Biliary Obstruction | Bile Duct Stones
-
NCT07337291CompletedCholedocholithiasis | Stent | Liver Circulation
-
NCT03849859TerminatedPlastic Stent Occlusion
-
NCT04595058CompletedPancreatic Cancer | Biliary Tract Neoplasms | Biliary Obstruction
-
NCT06133023Not yet recruitingPancreatitis | Pancreatic Pseudocyst | Pancreatic Fluid Collection
-
NCT01398917UnknownPrimary Sclerosing Cholangitis
-
NCT02685865CompletedPancreatic Collection | Infected Pancreatic Necrosis | Acute Pancreatic Fluid Collection | Pancreatic and Peripancreatic Necrosis | Symptomatic Pancreatic Necrosis
-
NCT03439020CompletedMalignant Biliary Stricture